Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine

[1]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[2]  Nouri Nayerossadat,et al.  Viral and nonviral delivery systems for gene delivery , 2012, Advanced biomedical research.

[3]  W. Wold,et al.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. , 2014, Current gene therapy.

[4]  Joo‐Hang Kim,et al.  Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy , 2002, Cancer Gene Therapy.

[5]  A. Fischer,et al.  Thérapie génique des déficits immunitaires sévères : preuve de principe d’efficacité et problèmes soulevés. Thérapie génique, déficits immunitaires, rétrovirus, lentivirus, génome , 2005 .

[6]  T. He,et al.  Retinoic Acids Potentiate BMP9-Induced Osteogenic Differentiation of Mesenchymal Progenitor Cells , 2010, PloS one.

[7]  M. Tagawa,et al.  Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China , 2008, Drug design, development and therapy.

[8]  T. He,et al.  A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. , 2009, Stem cells and development.

[9]  G. Calin,et al.  Progresses towards safe and efficient gene therapy vectors , 2015, Oncotarget.

[10]  A. Fischer,et al.  [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome]. , 2005, Bulletin de l'Academie nationale de medecine.

[11]  Tong-Chuan He,et al.  Potential Use of Sox9 Gene Therapy for Intervertebral Degenerative Disc Disease , 2003, Spine.

[12]  A. Ristimäki,et al.  Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. , 2010, Cancer research.

[13]  W. Walther,et al.  Viral vectors for gene transfer: a review of their use in the treatment of human diseases. , 2000, Drugs.

[14]  F. Graham,et al.  Development of a FLP/frt system for generating helper-dependent adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Jedd D. Wolchok,et al.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.

[16]  C. Kao,et al.  Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. , 2005, Cancer research.

[17]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[18]  C. Yun,et al.  Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers , 2013, Cancer Gene Therapy.

[19]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Lowenstein,et al.  Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[22]  Herpesvirus vectors in gene therapy. , 2010, The open virology journal.

[23]  M. Metzker,et al.  Optimization of the helper-dependent adenovirus system for production and potency in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Fox.  US authorities uphold suspension of SCID gene therapy , 2003, Nature Biotechnology.

[25]  R. Manservigi,et al.  HSV Recombinant Vectors for Gene Therapy. , 2010, The open virology journal.

[26]  J. Szatkowski,et al.  Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery , 2004, Gene Therapy.

[27]  Z. Izsvák,et al.  Sleeping Beauty Transposition , 2015, Microbiology spectrum.

[28]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[29]  Y. Ikeda,et al.  Lentiviral vectors: basic to translational. , 2012, The Biochemical journal.

[30]  David V Schaffer,et al.  Viral Vectors for Gene Therapy: Translational and Clinical Outlook. , 2015, Annual review of biomedical engineering.

[31]  H. Ertl,et al.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.

[32]  S. Yla-Herttuala,et al.  Gene therapy for malignant glioma: current clinical status. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  R. Desrosiers,et al.  Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  N. Saijo,et al.  Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. , 1995, Human gene therapy.

[36]  W. C. Groat,et al.  Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain , 2009, Gene Therapy.

[37]  M. Kay,et al.  Approaches for generating recombinant adenovirus vectors. , 2001, Advanced drug delivery reviews.

[38]  M. Muñoz-López,et al.  DNA Transposons: Nature and Applications in Genomics , 2010, Current genomics.

[39]  E. Galanis,et al.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.

[40]  R. Ortíz-López,et al.  Oncolytic virotherapy. , 2008, Annals of hepatology.

[41]  P. van de Putte,et al.  Efficient cDNA cloning by direct phenotypic correction of a mutant human cell line (HPRT-) using an Epstein-Barr virus-derived cDNA expression vector. , 1991, Nucleic Acids Research.

[42]  D. Nettelbeck,et al.  Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. , 2002, Cancer research.

[43]  R. Buckley.  Gene therapy for SCID—a complication after remarkable progress , 2002, The Lancet.

[44]  G. Zych,et al.  Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.

[45]  J. Mikkelsen,et al.  DNA transposon-based gene vehicles - scenes from an evolutionary drive , 2013, Journal of Biomedical Science.

[46]  N. Sullivan,et al.  Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. , 2015, Current opinion in immunology.

[47]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[48]  F. Spencer,et al.  Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  F. Spertini,et al.  Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. , 2016, The Lancet. Infectious diseases.

[50]  F. Kloss,et al.  Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes , 2003, Gene Therapy.

[51]  Y. Naomoto,et al.  Adenovirus-mediated cancer gene therapy and virotherapy (Review). , 2009, International journal of molecular medicine.

[52]  A. Hill,et al.  Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure , 2014, PloS one.

[53]  D. Mehrotra,et al.  Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults , 2009, Clinical and Vaccine Immunology.

[54]  A. Mountain,et al.  Gene therapy: the first decade. , 2000, Trends in biotechnology.

[55]  T. Kafri,et al.  Gene delivery by lentivirus vectors , 2007, Molecular biotechnology.

[56]  L. Medina-Kauwe,et al.  Regulatable Gutless Adenovirus Vectors Sustain Inducible Transgene Expression in the Brain in the Presence of an Immune Response against Adenoviruses , 2006, Journal of Virology.

[57]  A. Jauch,et al.  Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. , 2003, Blood.

[58]  L. Seymour,et al.  Adenovirus: teaching an old dog new tricks. , 2011, Human gene therapy.

[59]  H. G. van der Poel,et al.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. , 2001, Cancer research.

[60]  A. Deisseroth,et al.  TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases , 2012, Cancer Gene Therapy.

[61]  D. Swenson,et al.  Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections , 2008, Clinical and Vaccine Immunology.

[62]  E. Kremer,et al.  Ebola virus vaccine: benefit and risks of adenovirus-based vectors , 2015, Expert review of vaccines.

[63]  M. Pistello,et al.  A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection against HSV-1 and HSV-2 Genital Infections , 2012, Journal of Virology.

[64]  K. Kinzler,et al.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system , 2007, Nature Protocols.

[65]  D. Kayda,et al.  Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  J. Roth.  Adenovirus p53 gene therapy , 2006, Expert opinion on biological therapy.

[67]  J. Glorioso,et al.  Multiple Applications For Replication‐Defective Herpes Simplex Virus Vectors , 2001, Stem cells.

[68]  S. Ghosh,et al.  Adenoviral vectors , 2006, Applied biochemistry and biotechnology.

[69]  G. Gao,et al.  State-of-the-art human gene therapy: part I. Gene delivery technologies. , 2014, Discovery medicine.

[70]  C. Scallan,et al.  Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. , 2013, Vaccine.

[71]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[72]  M. Ramachandra,et al.  Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents , 2005, Cancer Gene Therapy.

[73]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  T. He,et al.  Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials , 2010, Stem cells international.

[75]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[76]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[77]  K. Mansfield,et al.  Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.

[78]  Matteo Pellegrini,et al.  Epigenetic Reprogramming by Adenovirus e1a , 2008, Science.

[79]  M. Perricaudet,et al.  Recombinational construction in Escherichia coli of infectious adenoviral genomes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Jay R Lieberman,et al.  Gene therapy for bone regeneration. , 2013, Current pharmaceutical design.

[81]  S. Thorgeirsson,et al.  Adenovirus–mediated in vivo gene transfer and expression in normal rat liver , 1992, Nature Genetics.

[82]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[83]  Mario Roederer,et al.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge , 2014, Nature Medicine.

[84]  J. Mascola,et al.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. , 2010, Vaccine.

[85]  J. Engh,et al.  Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. , 2001, Human gene therapy.

[86]  T. He,et al.  Engineering the Rapid Adenovirus Production and Amplification (RAPA) Cell Line to Expedite the Generation of Recombinant Adenoviruses , 2017, Cellular Physiology and Biochemistry.

[87]  J. Goss,et al.  Herpes simplex virus-based nerve targeting gene therapy in pain management , 2014, Journal of pain research.

[88]  Balaji Balakrishnan,et al.  Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. , 2014, Current gene therapy.

[89]  P. Celec,et al.  Vectors and delivery systems in gene therapy. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[90]  B. Li,et al.  Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors , 2015, Expert opinion on biological therapy.

[91]  O. Mazda,et al.  Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. , 1997, Journal of immunological methods.

[92]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[93]  D. Curiel,et al.  Advancements in adenoviral based virotherapy for ovarian cancer. , 2009, Advanced drug delivery reviews.

[94]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[95]  Z. Izsvák,et al.  Transposons for gene therapy! , 2006, Current gene therapy.

[96]  T. He,et al.  BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. , 2011, Current gene therapy.

[97]  Steven J. Kass,et al.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. , 2011, Current gene therapy.

[98]  S. Buchbinder,et al.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine , 2010, Current opinion in HIV and AIDS.

[99]  P. Hermonat,et al.  Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy , 2015, International reviews of immunology.

[100]  J. Roth,et al.  Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck , 2009, Clinical Cancer Research.

[101]  S. Burgess,et al.  Integration target site selection for retroviruses and transposable elements , 2004, Cellular and Molecular Life Sciences CMLS.

[102]  C. Scallan,et al.  An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models , 2012, Clinical and Vaccine Immunology.

[103]  T. Einhorn,et al.  Bone Regeneration: New Findings and Potential Clinical Applications , 2001, The Journal of the American Academy of Orthopaedic Surgeons.

[104]  J. Nemunaitis,et al.  Head and neck cancer: Response to p53‐based therapeutics , 2011, Head & neck.

[105]  Yong Huang,et al.  Mutational Analysis of the N-Terminal DNA-Binding Domain of Sleeping Beauty Transposase: Critical Residues for DNA Binding and Hyperactivity in Mammalian Cells , 2004, Molecular and Cellular Biology.

[106]  R. J. Dumont,et al.  Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents. , 2003, Tissue engineering.

[107]  J. Hamid,et al.  A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity , 2013, Science Translational Medicine.

[108]  D. McCarty,et al.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.

[109]  K. Rapti,et al.  Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy. , 2015, Biochimica et biophysica acta.

[110]  T. Shirakawa.  The current status of adenovirus-based cancer gene therapy. , 2008, Molecules and cells.

[111]  J. Glorioso,et al.  Herpes vector–mediated expression of proenkephalin reduces bone cancer pain , 2002, Annals of neurology.

[112]  K. Kawakami,et al.  Comparative analysis of transposable element vector systems in human cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  D. Fink,et al.  A human trial of HSV-mediated gene transfer for the treatment of chronic pain , 2009, Gene Therapy.

[114]  J. Uney,et al.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells) , 2009, Cell Biology and Toxicology.

[115]  H. Faneca,et al.  Suicide gene therapy in cancer: where do we stand now? , 2012, Cancer letters.

[116]  I. Hyodo,et al.  E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer , 2009, Cancer Gene Therapy.

[117]  N. Senzer,et al.  A review of contusugene ladenovec (Advexin) p53 therapy. , 2009, Current opinion in molecular therapeutics.

[118]  S. Boden,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies , 2002, Spine.

[119]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[120]  A. Davison,et al.  Genetic content and evolution of adenoviruses. , 2003, The Journal of general virology.

[121]  J. Szatkowski,et al.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). , 2003, The Journal of bone and joint surgery. American volume.

[122]  N. Tordo,et al.  Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer , 2009, Genetic vaccines and therapy.

[123]  P. Kilgore,et al.  Ebola Virus Infection: Overview and Update on Prevention and Treatment , 2015, Infectious Diseases and Therapy.

[124]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[125]  R. Samulski,et al.  Viral vectors for gene delivery to the central nervous system , 2012, Neurobiology of Disease.

[126]  E. Kieff,et al.  Epstein-Barr virus vectors for gene delivery to B lymphocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[127]  G. Ciliberto,et al.  Genetic cancer vaccines: current status and perspectives , 2012, Expert opinion on biological therapy.

[128]  X. Chen,et al.  Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells , 2014, Gene Therapy.

[129]  Z. Cao,et al.  A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury , 2008, Neuroscience Letters.

[130]  T. Kafri.  Gene delivery by lentivirus vectors an overview. , 2004, Methods in molecular biology.

[131]  A. Engelman,et al.  The roles of cellular factors in retroviral integration. , 2003, Current topics in microbiology and immunology.

[132]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[133]  B. Dropulić.  Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. , 2011, Human gene therapy.

[134]  W. Yung,et al.  Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization , 2005, Cancer Gene Therapy.

[135]  Janka Mátrai,et al.  Recent advances in lentiviral vector development and applications. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[136]  T. Sakou.  Bone morphogenetic proteins: from basic studies to clinical approaches. , 1998, Bone.

[137]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[138]  M. Hitt,et al.  A convenient plasmid system for construction of helper‐dependent adenoviral vectors and its application for analysis of the breast‐cancer‐specific mammaglobin promoter , 2006, The journal of gene medicine.

[139]  A. Folgori,et al.  Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.

[140]  Jie Zhou,et al.  Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial , 2009, Anti-cancer drugs.

[141]  M. Kaplitt,et al.  Future and current surgical therapies in Parkinson's disease , 2003, Current opinion in neurology.

[142]  M. Giacca,et al.  Integration site selection by retroviruses. , 2004, AIDS reviews.

[143]  H. Ertl.  Progress in the development of hepatitis C virus vaccines. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[144]  L. Medina-Kauwe,et al.  Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[145]  F. Graham,et al.  Cre Levels Limit Packaging Signal Excision Efficiency in the Cre/loxP Helper-Dependent Adenoviral Vector System , 2002, Journal of Virology.

[146]  Andrew J. Pollard,et al.  Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults , 2015, Science Translational Medicine.

[147]  F. Liu,et al.  NEL-Like Molecule-1 (Nell1) Is Regulated by Bone Morphogenetic Protein 9 (BMP9) and Potentiates BMP9-Induced Osteogenic Differentiation at the Expense of Adipogenesis in Mesenchymal Stem Cells , 2017, Cellular Physiology and Biochemistry.

[148]  M. Kay,et al.  Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. , 1998, Human gene therapy.

[149]  Mauro Giacca,et al.  Virus-mediated gene delivery for human gene therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[150]  M. Mehtali,et al.  Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli , 1996, Journal of virology.

[151]  R. Samulski,et al.  AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. , 2014, Annual review of virology.

[152]  E. Berto,et al.  Development and application of replication-incompetent HSV-1-based vectors , 2005, Gene Therapy.

[153]  X. de la Cruz,et al.  The SV40 T antigen modulates CBP histone acetyltransferase activity. , 2003, Nucleic acids research.

[154]  N. Mazarakis,et al.  Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. , 2005, Human gene therapy.

[155]  H. Ertl,et al.  New insights on adenovirus as vaccine vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[156]  R. Ali,et al.  Ocular gene delivery using lentiviral vectors , 2011, Gene Therapy.

[157]  K. Chu,et al.  Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial , 2015, The Lancet.

[158]  T. Flotte,et al.  A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. , 1996, Human gene therapy.

[159]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[160]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[161]  S. Hammer,et al.  Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. , 2016, The Journal of infectious diseases.

[162]  S. Gray,et al.  Recent gene therapy advancements for neurological diseases. , 2013, Discovery medicine.

[163]  J. Xiang,et al.  Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. , 2005, Current gene therapy.

[164]  T. He,et al.  Canonical Wnt signaling acts synergistically on BMP9-induced osteo/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). , 2015, Biomaterials.

[165]  A. Epstein,et al.  HSV as a vector in vaccine development and gene therapy , 2008, Human vaccines.

[166]  H. Hirai,et al.  Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. , 1997, Biochemical and biophysical research communications.

[167]  J. Prieto,et al.  Self-inactivating helper virus for the production of high-capacity adenoviral vectors , 2011, Gene Therapy.

[168]  Yan Deng,et al.  Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-carriers , 2014, Theranostics.

[169]  R. Warren,et al.  Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.

[170]  M. Imperiale,et al.  BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control , 1996, Journal of virology.

[171]  K. Hunt,et al.  Adenoviral gene therapy. , 2002, The oncologist.

[172]  T A Einhorn,et al.  Growth Factor Regulation of Fracture Repair , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[173]  E. Small,et al.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[174]  T. He,et al.  Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system , 2015, Genes & diseases.

[175]  J. McCullers.  Influenza , 2012, Textbook of Clinical Pediatrics.

[176]  R. H. Smith,et al.  Adeno-associated virus integration: virus versus vector , 2008, Gene Therapy.

[177]  W. Doerfler,et al.  Insertion of Foreign DNA into an Established Mammalian Genome Can Alter the Methylation of Cellular DNA Sequences , 1999, Journal of Virology.

[178]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[179]  N. Wolfe,et al.  International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. , 2010, Vaccine.

[180]  Philippe Soriano,et al.  A gene trap vector system for identifying transcriptionally responsive genes , 2001, Nature Biotechnology.

[181]  L. Aguilar,et al.  Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development , 2011, Journal of cellular biochemistry.

[182]  A. Ehrhardt,et al.  New insights into stability of recombinant adenovirus vector genomes in mammalian cells. , 2012, European journal of cell biology.

[183]  A. Montag,et al.  Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[184]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[185]  T. Flotte.  Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[186]  T. He,et al.  Characterization of adenovirus-mediated gene transfer in rabbit flexor tendons. , 2005, Journal of Hand Surgery-American Volume.

[187]  N. Frahm,et al.  Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. , 2016, Annals of internal medicine.

[188]  R. Herzog,et al.  Progress and prospects: immune responses to viral vectors , 2010, Gene Therapy.

[189]  A. Kingsman,et al.  Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer of Aromatic l-Amino Acid Decarboxylase, Tyrosine Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene Expression, Dopamine Production, and Functional Improvement in a Rat Model of Parkinson's Disease. , 2002, The Journal of Neuroscience.

[190]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[191]  C. Darimont,et al.  Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization , 2003, Cell Death and Differentiation.

[192]  Juan Shi,et al.  An update on gene therapy in China. , 2009, Current opinion in molecular therapeutics.

[193]  T. He,et al.  Insulin-like Growth Factor 2 (IGF-2) Potentiates BMP-9-Induced Osteogenic Differentiation and Bone Formation , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[194]  J. Doudna,et al.  Expanding the Biologist's Toolkit with CRISPR-Cas9. , 2015, Molecular cell.

[195]  T. He,et al.  Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells , 2013, Journal of cellular and molecular medicine.

[196]  A. Montag,et al.  Regulation of osteogenic differentiation during skeletal development. , 2008, Frontiers in bioscience : a journal and virtual library.

[197]  Julian R. E. Davis,et al.  Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination , 2001, Nature Biotechnology.

[198]  T. He,et al.  Notch Signaling Augments BMP9-Induced Bone Formation by Promoting the Osteogenesis-Angiogenesis Coupling Process in Mesenchymal Stem Cells (MSCs) , 2017, Cellular Physiology and Biochemistry.

[199]  M. Rudnicki,et al.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[200]  David Garrick,et al.  Repeat-induced gene silencing in mammals , 1998, Nature Genetics.

[201]  M. Tagawa,et al.  Cancer therapy with local oncolysis and topical cytokine secretion. , 2008, Frontiers in bioscience : a journal and virtual library.

[202]  J. Dye,et al.  Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector , 2010, Clinical and Vaccine Immunology.

[203]  A Daluiski,et al.  The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. , 1999, The Journal of bone and joint surgery. American volume.

[204]  A. Baiker,et al.  Episomal vectors for gene therapy. , 2008, Current gene therapy.

[205]  Yang Bi,et al.  Mesenchymal stem cells: Molecular characteristics and clinical applications. , 2010, World journal of stem cells.

[206]  Z. Darżynkiewicz,et al.  Distinct patterns of MCM protein binding in nuclei of S phase and rereplicating SV40‐infected monkey kidney cells , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[207]  M. Perricaudet,et al.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.

[208]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[209]  W. Doerfler,et al.  Integration of foreign DNA and its consequences in mammalian systems. , 1997, Trends in biotechnology.

[210]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[211]  D. Nettelbeck,et al.  Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. , 2012, Trends in molecular medicine.

[212]  T. He,et al.  BMP9 signaling in stem cell differentiation and osteogenesis. , 2018, American journal of stem cells.

[213]  R. Lachmann,et al.  Herpes simplex virus‐based vectors , 2004, International journal of experimental pathology.

[214]  H. Fang,et al.  Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.

[215]  P. Aspenberg,et al.  Randomized Radiostereometric Study Comparing Osteogenic Protein-1 (BMP-7) and Autograft Bone in Human Noninstrumented Posterolateral Lumbar Fusion: 2002 Volvo Award in Clinical Studies , 2002, Spine.

[216]  M. Imperiale,et al.  Production of first generation adenovirus vectors: a review , 2000, Gene Therapy.

[217]  Wenzhong Li,et al.  Non-viral gene delivery methods. , 2013, Current pharmaceutical biotechnology.

[218]  T. He,et al.  Adenovirus-Mediated Gene Transfer in Mesenchymal Stem Cells Can Be Significantly Enhanced by the Cationic Polymer Polybrene , 2014, PloS one.

[219]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[220]  P. Sharp,et al.  Generation of adenovirus by transfection of plasmids. , 1983, Nucleic acids research.

[221]  M. Kitamura,et al.  Construction of adenovirus vectors through Cre-lox recombination , 1997, Journal of virology.

[222]  G. Haegeman,et al.  Episomal vectors for gene expression in mammalian cells. , 2000, European journal of biochemistry.

[223]  A. Reddi.  Bone Morphogenetic Proteins: From Basic Science to Clinical Applications , 2001, The Journal of bone and joint surgery. American volume.

[224]  Hoguen Kim,et al.  Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. , 2003, Human gene therapy.

[225]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[226]  Ronald H. A. Plasterk,et al.  Molecular mechanisms of transposition and its control , 1993, Cell.

[227]  M. Vähä-Koskela,et al.  Oncolytic viruses in cancer therapy , 2007, Cancer Letters.

[228]  J. Glorioso,et al.  Gene delivery using herpes simplex virus vectors. , 2002, DNA and cell biology.

[229]  M. Kay,et al.  A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[230]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[231]  A. Montag,et al.  BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury. , 2007, The Journal of bone and joint surgery. American volume.

[232]  Justine R. Smith,et al.  Persistence of Ebola Virus in Ocular Fluid during Convalescence. , 2015, The New England journal of medicine.

[233]  M. Pistello,et al.  Viral vectors: a look back and ahead on gene transfer technology. , 2013, The new microbiologica.

[234]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[235]  D. Anson.  The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery , 2004, Genetic vaccines and therapy.

[236]  A. Epstein,et al.  HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. , 2010, Current opinion in drug discovery & development.

[237]  P. Rennie,et al.  Targeted oncolytic herpes simplex viruses for aggressive cancers. , 2012, Current pharmaceutical biotechnology.

[238]  K. Pramod,et al.  Novel gene delivery systems , 2013, International journal of pharmaceutical investigation.

[239]  R. Crystal.  Adenovirus: the first effective in vivo gene delivery vector. , 2014, Human gene therapy.

[240]  S. Efstathiou,et al.  The use of herpes simplex virus-based vectors for gene delivery to the nervous system. , 1997, Molecular medicine today.

[241]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[242]  T. He,et al.  Adenoviral vector-mediated gene transfer for human gene therapy. , 2001, Current gene therapy.

[243]  W. Bowers,et al.  Herpes Virus Amplicon Vectors , 2009, Viruses.

[244]  M. Aghi,et al.  Oncolytic herpes simplex virus engineering and preparation. , 2012, Methods in molecular biology.

[245]  C. Mueller,et al.  Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[246]  P. Rakoczy,et al.  Adenovirus and adeno-associated virus vectors. , 2002, DNA and cell biology.

[247]  Sally Lehrman,et al.  Virus treatment questioned after gene therapy death , 1999, Nature.

[248]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[249]  G. Visner,et al.  Applications of Sleeping Beauty transposons for nonviral gene therapy , 2007, IUBMB life.

[250]  T. Matsuse,et al.  Crisis of adenoviruses in human gene therapy , 2000, The Lancet.

[251]  H. Schuitemaker,et al.  Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. , 2016, JAMA.